Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN)
出版年份 2019 全文链接
标题
Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN)
作者
关键词
-
出版物
Trials
Volume 20, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-12-20
DOI
10.1186/s13063-019-3951-x
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)
- (2018) T R Cottrell et al. ANNALS OF ONCOLOGY
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
- (2018) Patrick M. Forde et al. NEW ENGLAND JOURNAL OF MEDICINE
- RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer
- (2018) Elizabeth Ahern et al. OncoImmunology
- An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer
- (2018) Alexander Liede et al. OncoImmunology
- Neoadjuvant chemo/immunotherapy for the treatment of stages IIIA resectable non-small cell lung cancer (NSCLC): A phase II multicenter exploratory study—NADIM study-SLCG.
- (2018) Mariano Provencio-Pulla et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant atezolizumab + chemotherapy in resectable non-small cell lung cancer (NSCLC).
- (2018) Catherine A. Shu et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Initial results from a multicenter study (LCMC3).
- (2018) Valerie W. Rusch et al. JOURNAL OF CLINICAL ONCOLOGY
- Roles of the RANKL–RANK axis in antitumour immunity — implications for therapy
- (2018) Elizabeth Ahern et al. Nature Reviews Clinical Oncology
- RANK rewires energy homeostasis in lung cancer cells and drives primary lung cancer
- (2017) Shuan Rao et al. GENES & DEVELOPMENT
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Current Trends of Lung Cancer Surgery and Demographic and Social Factors Related to Changes in the Trends of Lung Cancer Surgery: An Analysis of the National Database from 2010 to 2014
- (2017) Samina Park et al. Cancer Research and Treatment
- Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma
- (2016) Mark J. Smyth et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
- (2016) J. Liu et al. Cancer Discovery
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint
- (2014) Matthew D Hellmann et al. LANCET ONCOLOGY
- Treatment of Stage I and II Non-small Cell Lung Cancer
- (2013) John A. Howington et al. CHEST
- A randomised trial comparing preoperative to perioperative chemotherapy in early-stage non-small-cell lung cancer (IFCT 0002 trial)
- (2013) Virginie Westeel et al. EUROPEAN JOURNAL OF CANCER
- Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid: Subgroup Analysis from a Randomized Phase 3 Study
- (2012) Giorgio Vittorio Scagliotti et al. Journal of Thoracic Oncology
- Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab
- (2012) David L. Lacey et al. NATURE REVIEWS DRUG DISCOVERY
- Recent trends in resection rates among non-small cell lung cancer patients in England
- (2012) Sharma P Riaz et al. THORAX
- Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
- (2011) David H. Henry et al. JOURNAL OF CLINICAL ONCOLOGY
- Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Non–Small-Cell Lung Cancer
- (2010) Enriqueta Felip et al. JOURNAL OF CLINICAL ONCOLOGY
- Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group
- (2008) Jean-Pierre Pignon et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search